close icon

Bank of America Twenty Months Later

Bank of America Corp. stock closed at 14.42 yesterday. In 2015, the stock suffered a sell-off from as high as 18.42 dollars a share down to 10.94 by February, 2016. Could this slump be expected and is the current recovery going to continue?

On January 8th, 2015, nearly twenty months ago, we published “Bank of America Set to Extend Decline” to prepare investors for the upcoming weakness. “It does not look like a stock to invest in right now” was the last sentence in that article. The chart and analysis this conclusion was based on is given below.
bank of america 8.1.15
Except for this chart, we did not need anything else to form our bearish opinion on Bank of America stock. First of all, the Elliott Wave Principle suggested it was trading near the end of the final phase of a five-wave impulse. According to the theory, every impulse is followed by a three-wave correction in the opposite direction. In addition, the relative strength index was showing the typical bearish divergence between the last two motive waves within the sequence – 3 and 5. As the update chart below proves, technical analysis serves us not only in the short term.
bank of america 4.8.16
A little relabeling was needed, because wave 4 extended into a running flat, but it is true that Bank of America was definitely not a “buy” twenty months ago, in January, 2015. A year later, it had already lost about 40% of its value. Most people claim that technical analysis is useful only for short-term forecasts, while long-term developments depend entirely on fundamental factors. The Wave principle proved that when it comes to Bank of America, that is not the case.

Now, the 50% Fibonacci level seems to have stopped the bears in their tracks for now. Besides, the 5-3 wave cycle is pointing higher. If this is the correct count, Bank of America stock could be expected to climb above 18.42 from now on, since wave (C) is supposed to exceed the top of wave (A). 10.94 seems to be out of danger, at least for now.

Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

Undervalued Bristol Myers Stock Can Still Get Cheaper

It’s been almost two years since we shared our bullish stance on Bristol Myers stock. Shares in the pharmaceutical major were changing hands for less than $46 in April, 2019. The company had just announced its planned acquisition of Celgene for about $74 billion and Wall Street apparently didn’t like the risks involved. However, the…

Read More »

DraftKings on the Verge of Another 40% Decline

It’s been almost three and a half months since we examined DraftKings stock in October, 2020. The share price was hovering near $57 after a strong run from $10.60 to over $64 in just several months. The regulatory environment in the U.S. seemed to be warming up and many analysts hurried to issue their BUY…

Read More »

AMN Healthcare Stock to Suffer a 2020-Like Drop

AMN Healthcare Services provides workforce and staffing solutions to healthcare facilities in the U.S. The company is relatively small with a market capitalization of less than $4 billion. However, small companies can make for excellent returns if one happens to identify the winners. And indeed, between late-2011 and early-2020, AMN stock from under $4 to…

Read More »

Zoetis Stock Getting Ahead of Itself, Invites Correction

Based in Parsippany, NJ, Zoetis Inc. is an animal medicine and vaccine developer and manufacturer. The company went public in 2013 and has been enjoying steady growth since. With the stock currently above $160 a share, Zoetis holds a market cap of nearly $80 billion. For a profitable and growing company like Zoetis, a rising…

Read More »

CBOE Stock Looking Good After a Record Year

CBOE Global Markets Inc. is an equities, options and futures exchange operator in the U.S. and Europe. The company traces its roots back to Chicago in 1973, when it practically invented options trading in its present form. CBOE is literally part of the very infrastructure of modern financial markets. So it is not surprising that…

Read More »

Novo Nordisk Bulls Have an Elliott Wave Problem

Novo Nordisk A/S is a Danish pharmaceuticals major with a market cap of over $160 billion. People need their medication even in recessions, so the company’s business wasn’t as affected by the 2020 crisis as most other industries. Novo Nordisk remains a top-notch pharma with consistent profits and revenue and no debt whatsoever. And the…

Read More »

Lockheed ‘s Correction Still Unfolding as Expected

Almost a year and a half ago, in July 2019, we wrote that Lockheed Martin is likely “setting the stage for an unpleasant surprise.” The stock had just reached a new all-time high and was trading at $370 a share. Optimism was in the air and analysts were more bullish than ever. An indeed, fundamentally,…

Read More »

More analyses